

## Supplementary Online Content

Peter I, Dubinsky M, Bressman S, et al. Anti-tumor necrosis factor therapy and incidence of Parkinson disease among patients with inflammatory bowel disease. *JAMA Neurol*. Published online April 23, 2018. doi:10.1001/jamaneurol.2018.0605

### **eTable.** Patient Attrition

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable. Patient Attrition**

<b>Characteristic</b>	<b>No. of Patients</b>
Patients with at least two IBD diagnoses (ICD-9 555.x, 556.x or ICD-10 K50.xx, K51.xx)	657637
IBD patients who have at least 365 days of enrollment prior to and 182 days of enrollment after IBD index date	152880
IBD patients who are at least 18 years old on IBD index date	144703
IBD patients who have no PD claims (ICD-9 332.0 or ICD-10 G20) on or before IBD index date	144019
IBD patients who were able to be matched 1:5 to controls on age, gender, and year of index date	144018
Patients with UC	84436
Patients with CD	56507
Patients with indeterminate IBD	3075
Has some TNF exposure on or after IBD index date	13089

Note: UC and CD are determined by the majority of the inpatient claims first, and if the inpatient claims are tied then the majority of the outpatient claims is used to determine disease status.

If a distinction between UC and CD could not be made using these criteria, cases were classified as "indeterminate IBD".